Some of our recent news articles.
In March 2020, Fosun Pharma won the German BioNTech SE (referred to as "BioNTech" ) Authorized to exclusively develop and commercialize vaccine products for new coronaviruses based on its proprietary mRNA technology platform in mainland China, Hong Kong, Macao and Taiwan (same below). The vaccine is a biological product for prevention, and it is intended to be mainly used for the prevention of new coronavirus infection in people aged 18 and above. According to the latest public information of BioNTech, its new mRNA-based coronavirus vaccine has achieved positive results in phase 1/2 clinical trials. Among them, the two most advanced mRNA-based candidate vaccines BNT162b1 and BNT162b2 recently obtained the US Food and Drug Administration. (U.S. FDA) Fast Track designation is expected to become the fastest FDA approved mRNA vaccine. Subject to regulatory approval, BioNTech expects to start a global multi-center Phase 2b/3 clinical trial as early as later this month, with up to 30,000 participants expected to participate.
Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Shanghai Fosun Pharmaceutical.